JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2013, 62(6):249-254

Cationic Eudragit® Polymers as Excipients for Microparticles Prepared by Solvent Evaporation Method

Jakub Vysloužil*, Jana Bavoľárová, Martina Kejdušová, David Vetchý, Kateřina Dvořáčková
Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic

Three cationic acrylic polymers, i. e. Eudragit® RL, Eudragit® RS and Eudragit® E 100, were evaluated for the purpose of microparticles preparation by the solvent evaporation method. The practically insoluble drug mirtazapine and the freely soluble drug tramadol hydrochloride were selected for encapsulation as extreme limits of drug solubility. The prepared microspheres were analyzed by optical microscopy, drug content analysis and dissolution test. It was observed that Eudragit® RL did not provide microparticles while Eudragit® RS and Eudragit® E 100 yielded spherical microparticles. Samples prepared with mirtazapine showed sustained drug release whereas tramadol hydrochloride samples released the drug in a pattern similar to the immediate release profile. Eudragit® RS was found to be superior to Eudragit® E 100 in its encapsulation efficiency, drug loading and smaller mean size of microparticles.

Keywords: microparticles; solvent evaporation; sustained drug release; Eudragit®

Received: September 13, 2013; Accepted: October 29, 2013; Published: June 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vysloužil J, Bavoľárová J, Kejdušová M, Vetchý D, Dvořáčková K. Cationic Eudragit® Polymers as Excipients for Microparticles Prepared by Solvent Evaporation Method. Čes. slov. farm. 2013;62(6):249-254.
Download citation

References

  1. Kumar M. N. V. R. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 2000; 3, 234-258.
  2. Vasir J. K., Tambwekar K., Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003; 255, 13-32. Go to original source... Go to PubMed...
  3. Tran V. T., Benoît J. P., Venier-Julienne M. C. Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? Int J Pharm 2011; 407, 1-11. Go to original source... Go to PubMed...
  4. Gelperina S., Kisich K., Iseman M. D., Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care 2005; 172, 1487-1490. Go to original source... Go to PubMed...
  5. Kim S. J., Hahn S. K., Kim M. J., Kim D. H., Lee Y. P. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Control Release 2005; 104, 323-335. Go to original source... Go to PubMed...
  6. Thomasin C., Corradin G., Men Y., Merkle H. P., Gander B. Tetanus toxoid and synthetic malaria antigen containing poly (lactide)/poly (lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J Control Release 1996; 41, 131-145. Go to original source...
  7. Jyothi N. V. N., Prasanna P. M., Sakarkar S. N., Prabha K. S., Ramaiah P. S., Srawan G. Y. Microencapsulation techniques, factors influencing encapsulation efficiency. J Microencapsul 2010; 27, 187-197. Go to original source... Go to PubMed...
  8. Tuncay M., Çaliş S., Kaş H. S., Ercan M. T., Peksoy I., Hincal A. A. Diclofenac sodium incorporated PLGA (50: 50) microspheres: formulation considerations and in vitro/in vivo evaluation. Int J Pharm 2000; 195, 179-188. Go to original source... Go to PubMed...
  9. Kirby D. J., Kaur R., Perrie Y. Formulation and Characterisation of PLGA Microspheres as Vaccine Adjuvants. In Flower D. R., Perrie Y. eds. Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines Springer, 1st ed. New York: Springer 2013. Go to original source...
  10. Zakeri-Milani P., Loveymi B. D., Jelvehgari M., Valizadeh H. The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 2013; 103, 174-181. Go to original source... Go to PubMed...
  11. Beck L. R., Cowsar D. R., Lewis D. H., Gibson J. W., Flowers C. E. New long-acting injectable microcapsule contraceptive system. Am J Obstet Gynecol 1979; 135, 419-426. Go to original source... Go to PubMed...
  12. Li M., Rouaud O., Poncelet D. Microencapsulation by solvent evaporation: State of the art for process engineering approaches. Int J Pharm 2008; 363, 26-39. Go to original source... Go to PubMed...
  13. Ogawa Y., Yamamoto M., Okada H., Yashiki T., Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly (lactic/glycolic) acid. Chem Pharm Bull 1988; 36, 1095-1103. Go to original source... Go to PubMed...
  14. Bodmeier R., McGinity J. W. Solvent selection in the preparation of poly (DL-lactide) microspheres prepared by the solvent evaporation method. Int J Pharm 1988; 43, 179-186. Go to original source...
  15. Patel R. S., Cho D. Y., Tian C., Chang A., Estrellas K. M., Lavin D., Furtado S., Mathiowitz E. Doxycycline delivery from PLGA microspheres prepared by a modified solvent removal method. J Microencapsul 2012; 29, 344-352. Go to original source... Go to PubMed...
  16. Hui J., Yu X. J., Zhang Y., Hu F. Q. Characterization of Anti-Cancer Drug Materials Loaded Poly (3-hydroxybutyrate- co-3-hydroxyhexanoate) Microspheres for Drug Delivery System in Biochemical Material System. Adv Mat Res 2012; 600, 137-143. Go to original source...
  17. Ashford M., Fell J. T., Attwood D., Woodhead P. J. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting. Int J Pharm. 1993; 91, 241-245. Go to original source...
  18. Rasool F., Ahmad M., Murtaza G., Khan H. M. S., Khan S. A. Pharmacokinetic Studies on Metoprolol-Eudragit Matrix Tablets and Bioequivalence Consideration with Mepressor®. Tropical Journal of Pharmaceutical Research 2012; 11, 281-287. Go to original source...
  19. Dave V. S., Fahmy R. M., Bensley D., Hoag S. W. Eudragit® RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets. Drug Dev Ind Pharm 2012; 38, 1240-1253. Go to original source... Go to PubMed...
  20. Cortesi R., Ravani L., Menegatti E., Esposito E., Ronconi F. Eudragit® microparticles for the release of budesonide: A comparative study. Indian J Pharm Sci 2012; 74, 415-421. Go to original source... Go to PubMed...
  21. Duarte A. R. C., Roy C., Vega-González A., Duarte C. M., Subra-Paternault P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int J Pharm 2007; 332, 132-139. Go to original source... Go to PubMed...
  22. http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/protective-formulations/e100/Pages/default.aspx
  23. Saravanan M., Bhaskar K., Maharajan G., Pillai K. S. Ultrasonically controlled release and targeted delivery of diclofenac sodium via gelatin magnetic microspheres. Int J Pharm 2004; 283, 71-82. Go to original source... Go to PubMed...
  24. Wang S. B., Chen A. Z., Weng L. J., Chen M. Y., Xie X. L. Effect of Drug-loading Methods on Drug Load, Encapsulation Efficiency and Release Properties of Alginate/Poly-L-Arginine/Chitosan Ternary Complex Microcapsules. Macromol Biosci 2004; 4, 27-30. Go to original source... Go to PubMed...
  25. Haznedar S., Dortunc B. Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide. Int J Pharm 2004; 269, 131-140. Go to original source... Go to PubMed...
  26. European Pharmacopoeia Online http://online6.edqm.eu/ep708/
  27. Vetchý D., Vetchá M., Rabišková M., Gryczová E., Bartošíková L. Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug. Medicina (Kaunas) 2007; 43, 326-331. Go to original source...
  28. Singh V., Chaudhary A. K. Preparation of Eudragit E100 microspheres by modified solvent evaporation method. Acta Pol Pharm 2011; 68, 975-980.
  29. Basu S. K., Adhiyaman R. Preparation and Characterization of Nitrendipine-loaded Eudragit RL 100 Microspheres Prepared by an Emulsion-Solvent Evaporation Method. Tropical Journal of Pharmaceutical Research 2008; 7, 1033-1041. Go to original source...
  30. Alhnan M. A., Basit A. W. Engineering polymer blend microparticles: An investigation into the influence of polymer blend distribution and interaction. Eur J Pharm Sci 2011; 42, 30-36. Go to original source... Go to PubMed...
  31. El-Kamel A. H., Sokar M. S., Al Gamal S. S., Naggar V. F. Preparation and evaluation of ketoprofen floating oral delivery system. Int J Pharm. 2001; 220, 13-21. Go to original source... Go to PubMed...
  32. Khatun M., Islam S. M. A., Akter P., Quadir M. A., Reza M. S. Controlled release of naproxen sodium from Eudragit RS 100 transdermal film. Dhaka University Journal of Pharmaceutical Sciences 2004; 3, 1-2. Go to original source...
  33. Cerea M., Zheng W., Young C. R., McGinity J. W. A novel powder coating process for attaining taste masking and moisture protective films applied to tablets. Int J Pharm 2004; 279, 127-139. Go to original source... Go to PubMed...
  34. Guzman M. L., Manzo R. H., Olivera M. E. Eudragit E100 as a Drug Carrier: The Remarkable Affinity of Phosphate Ester for Dimethylamine. Mol Pharmaceutics 2012; 9, 2424-2433. Go to original source... Go to PubMed...
  35. Damgé C., Maincent P., Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 2007; 117, 163-170. Go to original source... Go to PubMed...
  36. Hanamura T. Experimental study of acrylic resin coated gentamicin tablets for local antibiotic therapy. Nihon Seikeigeka Gakkai zasshi 1984; 58, 555-565.
  37. Stallmann H. P., Faber C., Bronckers A. L., Amerongen A. V. N., Wuisman P. I. In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile. BMC Musculoskelet Disord 2006; 7, 1-8. Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.